Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and price target from Evercore ISI analyst Liisa Bayko today. The company’s shares closed yesterday at $397.58.
According to TipRanks, Bayko is a 4-star analyst with an average return of 8.8% and a 43.75% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Madrigal Pharmaceuticals, and Theravance Biopharma.
In addition to Evercore ISI, Vertex Pharmaceuticals also received a Buy from J.P. Morgan’s Jessica Fye in a report issued today. However, on April 8, RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).
The company has a one-year high of $448.40 and a one-year low of $316.43. Currently, Vertex Pharmaceuticals has an average volume of 1.28M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vertex Pharmaceuticals (VRTX) Company Description:
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
Read More on VRTX:
- M&A: Vertex Bolsters its Drug Portfolio with Alpine Deal
- RBC says pain opinion leader ‘notably negative’ on Vertex’s VX-548
- Truist pharmaceuticals analyst holds an analyst/industry conference call
- Vertex announces acceptance of NDS for exagamglogene autotemcel
- Vertex Pharmaceuticals advances inaxaplin into Phase 3 portion of trial
